219 related articles for article (PubMed ID: 26936336)
1. Development of a tail vein transection bleeding model in fully anaesthetized haemophilia A mice - characterization of two novel FVIII molecules.
Johansen PB; Tranholm M; Haaning J; Knudsen T
Haemophilia; 2016 Jul; 22(4):625-31. PubMed ID: 26936336
[TBL] [Abstract][Full Text] [Related]
2. Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model.
Pastoft AE; Ezban M; Tranholm M; Lykkesfeldt J; Lauritzen B
Haemophilia; 2013 Nov; 19(6):913-9. PubMed ID: 23730746
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs.
Agersø H; Stennicke HR; Pelzer H; Olsen EN; Merricks EP; Defriess NA; Nichols TC; Ezban M
Haemophilia; 2012 Nov; 18(6):941-7. PubMed ID: 22812621
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
[TBL] [Abstract][Full Text] [Related]
6. Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP.
Pickering W; Hansen M; Kjalke M; Ezban M
J Thromb Haemost; 2016 Aug; 14(8):1579-87. PubMed ID: 27241682
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FW; Lentz SR; Nemes L; Poulsen LH; Santagostino E; You CW; Clausen WH; Jönsson PG; Oldenburg J;
Thromb Haemost; 2017 Jan; 117(2):252-261. PubMed ID: 27904904
[TBL] [Abstract][Full Text] [Related]
8. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.
Hampton K; Chowdary P; Dunkley S; Ehrenforth S; Jacobsen L; Neff A; Santagostino E; Sathar J; Takedani H; Takemoto CM; Négrier C
Haemophilia; 2017 Sep; 23(5):689-696. PubMed ID: 28470862
[TBL] [Abstract][Full Text] [Related]
9. Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.
Ezban M; Vad K; Kjalke M
Eur J Haematol; 2014 Nov; 93(5):369-76. PubMed ID: 24797664
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
[TBL] [Abstract][Full Text] [Related]
11. Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A.
Takedani H; Hirose J
Drug Des Devel Ther; 2015; 9():1767-72. PubMed ID: 25848213
[TBL] [Abstract][Full Text] [Related]
12. Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).
Curry N; Albayrak C; Escobar M; Andre Holme P; Kearney S; Klamroth R; Misgav M; Négrier C; Wheeler A; Santagostino E; Shima M; Landorph A; Tønder SM; Lentz SR
Haemophilia; 2019 May; 25(3):373-381. PubMed ID: 30817066
[TBL] [Abstract][Full Text] [Related]
13. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.
Hillarp A; Bowyer A; Ezban M; Persson P; Kitchen S
Haemophilia; 2017 May; 23(3):458-465. PubMed ID: 28198071
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.
Brand B; Gruppo R; Wynn TT; Griskevicius L; Lopez Fernandez MF; Chapman M; Dvorak T; Pavlova BG; Abbuehl BE
Haemophilia; 2016 Jul; 22(4):e251-8. PubMed ID: 27328112
[TBL] [Abstract][Full Text] [Related]
16. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.
Dumont JA; Liu T; Low SC; Zhang X; Kamphaus G; Sakorafas P; Fraley C; Drager D; Reidy T; McCue J; Franck HW; Merricks EP; Nichols TC; Bitonti AJ; Pierce GF; Jiang H
Blood; 2012 Mar; 119(13):3024-30. PubMed ID: 22246033
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human prothrombin (MEDI8111) prevents bleeding in haemophilia A and B mice.
Hansson KM; Lindblom A; Elg M; Lövgren A
Haemophilia; 2016 May; 22(3):453-61. PubMed ID: 26635073
[TBL] [Abstract][Full Text] [Related]
18. Cases of less-than-expected FVIII activity in previously treated patients during post-marketing surveillance of N8-GP.
Oldenburg J; Benson G; Chowdary P; Halimeh S; Matsushita T; Nørland A; Wahid MN; Nemes L
Haemophilia; 2023 Nov; 29(6):1475-1482. PubMed ID: 37729439
[TBL] [Abstract][Full Text] [Related]
19. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
Kulkarni R; Karim FA; Glamocanin S; Janic D; Vdovin V; Ozelo M; Rageliene L; Carboni E; Laguna P; Dobaczewski G; Seremetis S; Lindblom A; Santagostino E
Haemophilia; 2013 Sep; 19(5):698-705. PubMed ID: 23651313
[TBL] [Abstract][Full Text] [Related]
20. An overview of turoctocog alfa pegol (N8-GP; ESPEROCT
Ezban M; Hansen M; Kjalke M
Haemophilia; 2020 Jan; 26(1):156-163. PubMed ID: 31809565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]